

Rune Midgard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5313568/publications.pdf>

Version: 2024-02-01

30
papers

1,195
citations

430874

18
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

1524
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2008, 7, 690-695.	10.2	229
2	Ï‰-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study). <i>Archives of Neurology</i> , 2012, 69, 1044-51.	4.5	123
3	Vitamin D and disease activity in multiple sclerosis before and during interferon-Î² treatment. <i>Neurology</i> , 2012, 79, 267-273.	1.1	113
4	Late Onset Myasthenia Gravis Is Associated with HLA DRB1*15:01 in the Norwegian Population. <i>PLoS ONE</i> , 2012, 7, e36603.	2.5	105
5	Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991. <i>Brain</i> , 1996, 119, 203-211.	7.6	70
6	Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1833-1840.	3.0	57
7	Body mass index influence interferon-beta treatment response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 288, 92-97.	2.3	56
8	Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. <i>Journal of Neurology</i> , 2013, 260, 1481-1488.	3.6	50
9	Impairment, disability and handicap in multiple sclerosis A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway. <i>Journal of Neurology</i> , 1996, 243, 337-344.	3.6	46
10	Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 451-457.	3.0	39
11	Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1028-1034.	3.0	38
12	Infections in Childhood and Adolescence in Multiple Sclerosis. <i>Neuroepidemiology</i> , 1993, 12, 61-69.	2.3	27
13	Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1569-1580.	3.0	26
14	Prevalence and incidence of multiple sclerosis in Oppland County - a cross-sectional population-based study in a landlocked county of Eastern Norway. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 250-257.	2.1	25
15	Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 60-65.	2.3	25
16	Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis – Association and Prediction. <i>PLoS ONE</i> , 2013, 8, e54417.	2.5	22
17	No association of tobacco use and disease activity in multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e260.	6.0	21
18	Vitamin D status and effect of interferon-Î²1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 280, 21-28.	2.3	19

#	ARTICLE	IF	CITATIONS
19	Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 213-219.	3.0	17
20	Incidence of cancer in multiple sclerosis before and after the treatment era – a registry- based cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103209.	2.0	15
21	High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	6.0	14
22	Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 323, 73-77.	2.3	13
23	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102801.	2.0	13
24	Cognitive and Emotional Impairment after Minor Stroke and Non-ST-Elevation Myocardial Infarction (NSTEMI): A Prevalence Study. <i>Stroke Research and Treatment</i> , 2019, 2019, 1-9.	0.8	8
25	The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	8
26	Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 849-857.	1.9	7
27	Life-threatening acute pancreatitis associated with interferon beta-1a treatment in multiple sclerosis. <i>Neurology</i> , 2005, 65, 170-171.	1.1	5
28	Factors influencing employment after minor stroke and NSTEMI. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105036.	1.6	3
29	Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 376-377.	3.7	1
30	The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons. <i>Epidemiology</i> , 2011, 22, S60.	2.7	0